Latest news

• Is acquisitive Celgene now eyeing CAR-T specialist Juno?

  Interest in CAR-T therapies in particular has been growing since the first two products in the category - Novartis’ Kymriah (tisagenleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) - were approved for

• Spark’s Luxturna becomes US’s first approved gene therapy

  Novartis’ first-approved CAR-T therapy Kymriah (tisagenleucel) has been priced at $475, 000 per course in the US, but a recent Bloomberg report suggests some patients are finding it difficult

• Alcon spin-out more likely but not imminent, says Novartis

  The results are the first for Novartis since it scored a world first - claiming approval for its CAR-T Kymriah (tisagenleucel) and introducing a new type of immunotherapy for cancer - and

• Vas Narasimhan takes top Novartis job on Jimenez departure

  The new CEO will take over just as Novartis' has scored a world first - claiming approval for its CAR-T Kymriah (tisagenleucel) - which introduces a new type of immunotherapy for cancer

• Novartis claims first CAR-T approval, setting $475k price tag

  Kymriah receives FDA nod to treat ALL patients. The FDA has approved Novartis’ cancer immunotherapy tisagenleucel (CTL019) under the Kymriah brand name, setting a $475, 000 price per course for the